home

Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.

TrendBristol-Myers Squibb2015-11-03 17:36 Read   258

Bristol-Myers Squibb gains full rights to Cardioxyl’s novel nitroxyl (HNO) donor in Phase 2 development for acute decompensated heart failure.Strengthens Bristol-Myers Squibb’s pipeline and strategic focus on heart failure.

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer

TrendMacroGenics2015-10-23 11:07 Read   372

Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer

CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute to Develop Novel CAR-T Technology

TrendPharmacodia.com2015-10-17 00:00 Read   393

CARsgen Therapeutics, a private and venture backed company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, today provided a business and clinical update on its immunotherapy programs.

Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program

TrendPharmacodia.com2015-10-16 00:00 Read   271

Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program.

AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial

TrendPharmacodia.com2015-10-16 00:00 Read   1792

Peregrine announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial.

Johnson & Johnson Innovation Announces Collaborations with Canadian Biotechs Novera Therapeutics, Inc. and enGene, Inc.

TrendPharmacodia.com2015-10-15 00:00 Read   924

October 14, 2015, Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced collaborations with two Canadian biotechnology companies, Toronto-based Novera Therapeutics, Inc. and Montreal-based enGene, Inc.

UCL and Takeda Announce a New Research Partnership to Identify Novel Therapeutic Targets for Neurodegenerative Diseases

TrendPharmacodia.com2015-10-15 00:00 Read   373

October 14, 2015, UCL (University College London) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease.

Ajinomoto Althea, Inc. Expands Manufacturing Capabilities to Antibody Drug Conjugate (ADC) Fill Finish and Bioconjugation

TrendPharmacodia.com2015-10-15 00:00 Read   531

Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates.

Lilly signs a $1B deal to deepen its oncology ties with China's Innovent

TrendPharmacodia.com2015-10-13 00:00 Read   251

Eli Lilly ($LLY) has expanded its R&D partnership with China's Innovent Biologics, bringing in three potential immunotherapies for cancer and adding another $1 billion in potential value to the existing alliance.

Novartis buys a bigger stake in Gamida, stopping short of a $600M plunge

TrendPharmacodia.com2015-10-13 00:00 Read   191

Novartis is forging ahead with a prospective stem cell biotech buyout, agreeing to pay $35 million to grab a sizable equity stake in Gamida Cell while executing a short term option deal that will allow the pharma giant ($NVS) the right to gobble up the company for another $600 million split up between a $165 million upfront payout with the rest up for grabs in development and sales milestones.

BioMed Realty Enters Into Definitive Agreement To Be Acquired By Blackstone For $23.75 Per Share In $8 Billion Transaction

TrendPharmacodia.com2015-10-12 00:00 Read   280

BioMed Realty Trust, Inc. announced that it has entered into a definitive agreement with affiliates of Blackstone Real Estate Partners VIII, under which Blackstone will acquire all outstanding shares of common stock of BioMed Realty for $23.75 per share in an all-cash transaction valued at $8 billion.

TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer's and Frontotemporal Dementia

TrendPharmacodia.com2015-10-09 00:00 Read   369

TauRx Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, announced the completion of the final tranche of a US$135m equity financing that it launched in March.